FIRST-LINE ERLOTINIB VERSUS CISPLATIN/GEMCITABINE (GP) IN PATIENTS WITH ADVANCED EGFR MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC): INTERIM ANALYSES FROM THE PHASE 3, OPEN-LABEL, ENSURE STUDY | |
Wu, Yi-Long; Liam, Chong-Kin; Zhou, Caicun; Wu, Gang; Liu, Xiaoqing; Zhong, Zhaoyang; Lu, Shun; Cheng, Ying; Han, Baohui; Chen, Lei | |
2013 | |
关键词 | EGFR mutations Asian patients erlotinib NSCLC |
卷号 | 8 |
会议录 | JOURNAL OF THORACIC ONCOLOGY
![]() |
语种 | 英语 |
URL标识 | 查看原文 |
ISSN号 | 1556-0864 |
内容类型 | 会议论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/4904212 |
专题 | 复旦大学上海医学院 |
推荐引用方式 GB/T 7714 | Wu, Yi-Long,Liam, Chong-Kin,Zhou, Caicun,et al. FIRST-LINE ERLOTINIB VERSUS CISPLATIN/GEMCITABINE (GP) IN PATIENTS WITH ADVANCED EGFR MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC): INTERIM ANALYSES FROM THE PHASE 3, OPEN-LABEL, ENSURE STUDY[C]. 见:. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论